@BJones_Lead

Champion of the scientific community and mentorship. 🌟👨‍🔬📚

San Francisco
Joined August 2021
Brian Jones retweeted
Always happy to see a great African collaborator at a top international conference: here with Dr Eric Agboli from Ghana, who is doing a Post-Doctoral Fellowship at Bernhard Nocht Institute for Tropical Medicine in Germany. We work together tracking West Nile viruses in Africa and their global expansion #WHA2026
3
28
1,347
Brian Jones retweeted
Not so fast with tricuspid valve interventions: Analysis of the TRIC-I-HF Trial by @drjohnm sensible-med.com/p/not-so-fa…
1
323
What you eat after birth might decide how fast you age. A study found that higher birth weight was linked to slower biological aging across 11 organ systems, while breastfeeding was associated with slower aging of the gut and adrenal glands. onlinelibrary.wiley.com/doi/…
1
95
Brian Jones retweeted
A colonoscopy is not your only option for colorectal cancer screening. Our Dr. David Richards breaks down alternatives to find the test that's right for you. #EndCancer spr.ly/6011BH8RVh
2
4
18
3,226
We’re excited to welcome EBAMed and CEO Marcin Gołębicki as a Presenting Company at #InnovationSanDiego 2026. EBAMed’s #AI-powered technology aims to improve precision and safety in non-invasive cardiac radioablation. Register today: bit.ly/4juglw8
1
1
83
Brian Jones retweeted
Bladder cancer highlights for #ESMO26 . 4 randomised phase III studies in perioperative disease. VOLGA (EVD vs EVDT vs cystectomy; KN866 (GC+/-pembro) ENERGIZE (GC+/- nivo); KN905 (pembro vs cystectomy). Also, ctDNA data for EVP vs chemo in B15/EV304. No personalized cancer vaccine or RT +/- ICI data. In advanced disease: Long term data for Rll of EV vs EVP. More data with SAC-TMT/PD1. Also triplet data with EV/SG/PD1. No new breakthrough ADC or data on VEGF/PD1 bispecifics. @Annals_Oncology @myESMO @OncoAlert
38
94
5,613
5/5) This is just the tip of the iceberg. In today's deep dive, we don't just discuss visceral fat, we build a framework for what it's doing inside your body, and the evidence-backed strategies that actually target it. Link: staycuriousmetabolism.substa…
6
2
67
9,436
A massive new study involving over one million individuals has uncovered a powerful link between everyday heart health and long-term brain protection. Researchers have found that maintaining low cholesterol levels over a lifetime could significantly reduce the risk of developing dementia, offering a promising look at how preventative cardiovascular care doubles as cognitive armor. Scientists analyzed genetic data to understand how natural variations that mimic the effects of common cholesterol-lowering medications, such as statins, impact the brain. Because these genetic traits naturally keep non-HDL cholesterol low throughout a person's entire life, they provide a clear and uninterrupted picture of long-term health. The findings reveal that keeping cholesterol in check prevents the gradual buildup of blockages in the blood vessels that supply oxygen and vital nutrients to the brain, directly supporting neurological resilience. The magnitude of this protective effect is substantial and suggests that consistent cholesterol management starting in mid-life is a critical component of preserving memory and cognitive function. While short-term treatments in later years have sometimes shown mixed results, this expansive research highlights that early and sustained prevention is the true key to success. By taking proactive steps to manage cardiovascular health today, individuals are essentially building a strong, lifelong defense against cognitive decline in the decades to come. Publication paper: Liv Tybjærg Nordestgaard et al, Cholesterol‐lowering drug targets reduce risk of dementia: Mendelian randomization and meta‐analyses of 1 million individuals, Alzheimer's & Dementia. DOI: 10.1002/alz.70638
6
24
2
72
2,635
Brian Jones retweeted
Op-ed @statnews by @HHSGov Chief Economist and Chief Regulatory Officer @caseybmulligan: "A 340B hospital that buys another hospital or a physician practice can register more off-campus clinics and contract pharmacies and capture more spread. Hospital off-campus clinic sites grew from about 7,000 in 2013 to more than 34,000 in 2023, often in neighborhoods that are wealthier and better-insured than that of the parent hospital. Contract pharmacies grew from roughly 1,300 in 2010 to more than 31,000 by mid-2026, dominated by the largest chains. With greater bargaining power after acquisitions, hospital systems can negotiate higher commercial prices for health care services, which can in turn raise premiums. Newly acquired hospital outpatient sites can also add facility fees to non-drug services. The effects of 340B show up as larger, more expensive hospital systems and a bigger bill for patients, employers, and taxpayers." Full article: statnews.com/2026/10/08/340b…
340B Program Timeline & Growth h/t Aiden Lee, Khrysta Dunkel @KhrystaDunkel, Eden Volkov, Sebastian Askar, @caseybmulligan
9
24
4
70
6,585
Brian Jones retweeted
The Scan Found Something We Weren’t Looking For: That’s the Problem. Don’t turn people into patients, writes Prof @JamesStein18 jamesstein18.substack.com/p/…
2
4
11
1,111
📑 Nanomaterial Synthesis in Deep Eutectic Solvents 👉 mdpi.com/3646796 This review examines electrochemical routes to metals, alloys, oxides and carbon-based composites, covering morphology control, nucleation, recycling and scale-up. #Electrochemistry #Nanomaterials
11
23
389
Relevant data point: according to an Oliver Wyman survey, we are already close to patients trusting AI more than clinicians. That doesn’t mean that clinicians get replaced. It does mean that patients will be more and more involved in self-direction with the help of AI. nitter.cf/nikillinit/status/2108…
there's a common belief in healthcare among providers that most people would rather trust a doctor than AI - but I think we're not far from a tipping point here Was interesting to see this Oliver Wyman survey of consumers and see how close we are to people trusting AI more than the clinician On top of that the number of times where the AI and clinician disagree is increasing, with people MORE often doing something other than what the clinician directly said This is heading for a collision course at some point
1
3
299
By 2030, most Americans will access healthcare neither by digging through insurance network directories, nor through Google search, nor via a primary care doc, nor through some bolt on thing your employer bought. Most people will start with chat. Chat will have your medical records and insurance as context. Chat will answer your questions, find appropriate doctors, show prices, and schedule appointments and lab tests. Handoffs will be seamless and your doctors will always receive your full medical records from chat. This will get more powerful as FDA permits AI to take low risk medical actions like prescribing or refilling certain drugs and making certain referrals. Ant is testing a version of this in Guangzhou - screenshots below. People who want to do things the old way will be able to do so. But most people will pick chat. Chat is an important part of the future of healthcare in America, like it or not.
We need Grok @bot to be able to integrate w healthcare data the ultimate healthcare experience is: > agent gets your data and biometrics > agent studies medical literature on what you need > agent books your visits/labs/meds > you get better > repeat
23
16
14
154
62,507
Recent observational study found that vegans have a higher risk of colorectal cancer than meat eaters. "should be interpreted with caution" - but sure cuts against the narrative. pmc.ncbi.nlm.nih.gov/article…
13
26
3
239
28,557
#FollowFriday Meet Kolade Olabode, MD (@Kolade__Olabode), a fourth-year radiation oncology resident whose research focuses on lung cancer, brain metastases and radiation therapy. Follow him for the latest in radiation oncology research. #MoffittAmbassadors
1
4
568
🩻 Case Study of the Week - Diagnosis Time! Sweat gland carcinoma of the breast. The differential diagnosis includes other common cutaneous cancers such as basal cell carcinoma, squamous cell carcinoma, or metastatic carcinoma of the skin. Other possible differentials include hidradenoma and primary ductal breast malignancy. 🔗 See all the case details, more images, and the diagnosis zurl.co/0lHLm #Radiology #Imaging #Radiologist #MedicalImaging #BreastCancerAwarenessMonth #BreastCancerAwareness #BreastCancer #COW #CaseOfTheWeek
1
4
2
416
At #CellCoast2026, Moffitt’s Sameh Gaballa, MD (@samehgaballa), shares the latest updates on bispecific antibodies in lymphoma and their evolving role in treatment. Key takeaways: ➡️ The future of DLBCL treatment is moving toward chemotherapy-free approaches, including bispecific antibodies, novel combinations and CAR T-cell therapies. ➡️ Surovatamig (AZD0486), an investigational bispecific antibody, is showing promising activity in relapsed/refractory follicular lymphoma, with a 95% overall response rate and 85% complete response rate in an early study cohort. ➡️ Ongoing clinical trials are evaluating surovatamig across B-cell malignancies, including follicular lymphoma and large B-cell lymphoma, as researchers explore its potential in earlier treatment settings.
1
3
9
653
Never before in human history so many high-power individuals and groups working in the pharmaceutical industry came together to present their work, collaborate and partner to advance aging research as a platform for drug discovery. I was deeply privileged to document this pivotal meeting. Please find the photos from #ARDD2026 by following this link: agingpharma.org/photos2026
🤖 Made with AI
1
6
1
37
2,371
Glad that someone noticed this. R&D productivity is extremely important. If we had more financial resources, I could start a program for pretty much every high-value protein target using multiple therapeutic modalities at once. AI is no longer the moat. The moat is operational efficiency, monkey and human patient resource. And the real bottleneck is in the clinic.
This is a joke that Insilco’s valuation is ~$4 billion and Isomorphic has nothing and $50 billion valuation. Insilico. Phase 3, multiple in studies 13 INDs?, 40 drug candidates I have no affiliation with Insilico or stock or anything. Just know drug development milestones.
6
11
2
111
6,053
🎉TimePie Longevity Forum is featured in @NatureAging! Appreciation to all the experts who contributed to the conversations shaping the future of longevity. @KejunYing @AMCuervoLab @prof_horvath @gladyshev_lab @susanna_rosi @Vinz_Sorrentino, et al. nature.com/articles/s43587-0…
3
6
253